Biotech
Analysis
Mesoblast Limited
Riding the scariest rollercoaster on the ASX
If you thought crypto investors need to have strong stomachs, spare a thought for the investors who try their luck in the biotech sector.
- by William Bennett
Latest
Sponsored
Bulls N' Bears
Hydration rehydrates share price with non-US asset sale
This week’s Bulls N’ Bears Runner of the Week is … Hydration Pharmaceuticals. The company sold its non-US assets for a sum five times its market capitalisation.
- by Craig Nolan
It introduced Ozempic to the world. Now it must remake itself
Danish drugmaker Novo Nordisk has eclipsed French luxury group LVMH to become Europe’s most valuable company – thanks to demand for diabetes and weight-loss drugs.
- by Eshe Nelson
The artificial heart set to transform medicine – and the Aussie who invented it
Biomedical engineer Daniel Timms lost his father to heart disease, but their kitchen-top tests helped him hone a radical idea.
- by Amanda Hooton
Magazine
Good Weekend
The April 20 Edition
The Aus-designed artificial heart set to revolutionise medicine | Preppers go mainstream | A sperm donor’s message to his progeny
Opinion
Health
Our track record in medical innovation can only be maintained with funding support
Australian researchers are responsible for a series of globally significant medical inventions and innovations.
- by The Herald's View
Future of medical research in doubt as question mark lingers over $45 million funding
The future of a government funding program which has assisted teams developing artificial hearts and turning spider venom into drug therapies is in doubt.
- by Mary Ward
Exclusive
Healthcare
His dad was dying. So Daniel built a world-first artificial heart – with pipes and magnets
Australia will spend $50 million building the world’s first long-term artificial heart, after the original prototype was built with pieces bought from Bunnings.
- by Sherryn Groch
Failed drug trial overshadows CSL’s bumper profits
Investors have punished the company’s share price for the second day in a row – despite it booking revenue of $12.3 billion for the half-year to December 31.
- by David Swan
Health behemoth CSL sheds $7b in value after heart drug fails trial
Shares in the blood plasma treatments maker were trading nearly 5 per cent lower following the results.
- by Millie Muroi
Exclusive
Education
Australia underspends on this key area. It may put national security at risk
Australia’s underinvestment in research is becoming a national security issue, some university heads argue, ahead of a landmark review and the AUKUS deal.
- by Sherryn Groch and Daniella White
Original URL: https://www.theage.com.au/topic/biotechnology-5v0